•  
  •  
  •  
  •  

2025-10-03 12:37:15

  • Home
  • Commodities
  • Industry News
  • IPO
  • Mutual Funds
  • Others
  • Research
  • Watch List
Latest News
  • Black Box Partners with Wind River to Accelerate Edge and Cloud Innovation Globally
  • Godrej Properties ranked #1 amongst global residential developers for its ESG practices by GRESB
  • Union Minister Shri. Prahlad Joshi launches Refex Green Mobility Operations in Delhi NCR
  • IHC Expands Global Portfolio with USD 1Bn investment in Sammaan Capital
  • Revolt Motors Strengthens Leadership Team with Appointment of Raghava Rao as Chief Business Officer

Keywords Selected:  Biosimilar

Stock Report

  • Biocon Biologics Secures U.S. Market Entry Date for Bosaya™ and Aukelso™, Denosumab Biosimilars
  • CuraTeQ Biologics Pvt Ltd completes Phase 3 Clinical Study for Denosumab Biosimilar
  • CuraTeQ Biologics receives approval for biosimilar Dazublys from UK's MHRA
  • Lupin announces licensing deal for Ranibizumab Biosimilar
  • Lupin and Zentiva Sign License and Supply Agreement for Commercializing Certolizumab
  • Lupin Ltd enters into agreement with Zentiva for biosimilar Certolizumab Pegol
  • Biocon Biologics Collaborates with National Cancer Society Malaysia
  • OneSource and Xbrane Biopharma Announce Biosimilars Manufacturing Partnership for the Global Markets
  • Biocon Biologics Receives Positive CHMP Opinions for Biosimilar Denosumab in Europe
  • CuraTeQ Biologics receives positive opinion for biosimilar Dazublys® from EMA
  • Biocon Biologics secures Market Entry Date for Yesafili™, an Interchangeable Biosimilar to Eylea®, in the U.S.
  • Biocon Biologics announces U.S. FDA Approval for Jobevne™, Biosimilar Bevacizumab, Expanding Its Oncology Portfolio
  • CuraTeQ Biologics received Marketing Authorization for Dyrupeg™, a pegylated filgrastim biosimilar
  • European Commission approves Biocon Biologics' Ustekinumab Biosimilar
  • CuraTeQ Biologics receives approval for oncology biosimilar Bevqolva from UK's MHRA
  • EMA's CHMP recommends approval of Biocon Biologics' YESINTEK®, biosimilar to J&J's Stelara®
  • U.S.FDA Approves Biocon Biologics' YESINTEK™, Bmab 1200 biosimilar to J&J's Stelara® (Ustekinumab)
  • Dr. Reddy's receives positive CHMP opinion from European Medicines Agency for its proposed Rituximab biosimilar
  • Zydus receives approval from COFEPRIS of Mexico to market Bhavaâ„¢ to treat various cancers
  • Zydus and Dr. Reddy's announce licensing agreement for co‐marketing of Pertuzumab biosimilar
  • EMA Approves Biocon Biologics' New mAbs Facility in India and Renews GMP Certifications for India and Malaysia Sites
  • Ipca Laboratories Ltd enters into technology transfer agreement with Omexa Formulary Pvt Ltd
  • CuraTeQ Biologics announces the successful Phase 1 clinical study outcome of their BP11 product
  • Biocon Biologics Secures Canada Market Entry Date for YESAFILI®, a Proposed Biosimilar to EYLEA®

Latest Post

  • Black Box Partners with Wind River to Accelerate Edge and Cloud Innovation Globally
  • Godrej Properties ranked #1 amongst global residential developers for its ESG practices by GRESB
  • Union Minister Shri. Prahlad Joshi launches Refex Green Mobility Operations in Delhi NCR
  • IHC Expands Global Portfolio with USD 1Bn investment in Sammaan Capital
  • Revolt Motors Strengthens Leadership Team with Appointment of Raghava Rao as Chief Business Officer


Announcement

To Advertise in our website please e-mail us at advertisement@equitybulls.com
Companies can send their Press Releases to pressrelease@equitybulls.com

Links

  • Home
  • Contact
  • Our Team

Contact

The website is developed and maintained by Chennai Scripts
C-4, Podhigai Flats, Pillayar Koil Street, Nesapakkam
Chennai
Tamil Nadu
India
600078
E-mail: chennaiscripts@gmail.com
Mobile Phone Number: +91-88776-69935
www.chennaiscripts.com

Website Created & Maintained by : Chennai Scripts
Nesapakkam, Chennai - 600 078,
Tamil Nadu, India

Disclaimer Copyright © - 2024